. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Curr Probl Surg. 2021 Jul 7;59(1):101030. doi: 10.1016/j.cpsurg.2021.101030

Table 15.

Neoadjuvant clinical trials.

Clinicaltrials.gov identifier	Study name	Phase / Status	Description of trial
NCT02036086 ³⁷²	Neoadjuvant Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma with Palpable Lymph Node Metastases	2 – Active, not recruiting	Neoadjuvant vemurafenib/cobimetinib in patients with BRAF V600 mutant stage IIIB-C melanoma
NCT01972347 ³⁷³	Neoadjuvant Dabrafenib/Trametinib for Stage IIIB-C BRAF V600 Mutation Positive Melanoma	2 – Active, not recruiting	Phase 2 study of neoadjuvant dabrafenib/trametinib in stage IIIB-C BRAF V600 mutant melanoma.
NCT04495010 ³⁷⁴	Neoadjuvant Nivolumab plus Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab plus Ipilimumab Followed by Adjuvant Observation Compared with Adjuvant Nivolumab in Treatment-Naïve High-risk Melanoma (CheckMate 7UA)	2 – Not yet recruiting	Neoadjuvant nivolumab/ipilimumab followed by adjuvant nivolumab versus neoadjuvant nivolumab/ipilimumab followed by observation versus adjuvant nivolumab in treatment-naïve high-risk melanoma